Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
1.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
4.2K
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can whole genome data analysis be used to personalize breast cancer care?

Translational cancer research·2026
Same author

<i>Hibiscus sabdariffa</i> calyx extract induces anti-proliferative and anti-migratory effects in ovarian cancer.

Journal of food science and technology·2026
Same author

Genome-Wide DNA Methylation Profiling Reveals Ancestry-Associated Epigenetic Reprogramming in Cervical Intraepithelial Neoplasia.

International journal of molecular sciences·2026
Same author

Extracellular vesicle delivery of Myricetin suppresses ovarian cancer through mitochondrial dynamics by downregulating the ECM1/NF-κB/TGFβ signaling pathway.

Scientific reports·2026
Same author

The effects of anti-Parkinsonian medications on bone mineral density: A systematic review.

Bone·2026
Same author

Interleukin-17A Orchestrates Lung Injury and Remodeling Through p53 and uPA System Crosstalk.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Mar 25, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.3K

Mitochondrial Reprogramming Regulates Breast Cancer Progression.

Anbarasu Kannan1, Robert B Wells2, Subramaniam Sivakumar3

  • 1Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 19, 2016
PubMed
Summary

Altered mitochondrial function, involving SH3GL2 and MFN2 proteins, impacts breast cancer progression. Loss of these proteins in tumors correlates with disease advancement and is detectable in exosomes, suggesting potential biomarkers.

More Related Videos

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

6.4K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Related Experiment Videos

Last Updated: Mar 25, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.3K
Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

6.4K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Area of Science:

  • Mitochondrial biology
  • Cancer research
  • Biomarker development

Background:

  • Mitochondrial dysfunction is implicated in cancer progression.
  • Identifying key regulators of mitochondrial function is crucial for understanding tumorigenesis.

Purpose of the Study:

  • To investigate the role of altered mitochondrial function in breast cancer progression.
  • To explore the potential of molecular alterations in mitochondrial proteins as exosome-based biomarkers.

Main Methods:

  • Characterized mitochondrial regulators SH3GL2 and MFN2 in breast cancer cells.
  • Assessed the impact of SH3GL2 overexpression and depletion on cancer phenotypes.
  • Analyzed SH3GL2 and MFN2 expression in human breast cancer tissues, lymph nodes, and exosomes.

Main Results:

  • SH3GL2 and MFN2 interplay in mitochondria reduced metastases and primary tumor growth.
  • SH3GL2 overexpression induced mitochondrial changes (superoxide production, cytochrome C release).
  • Loss of SH3GL2 and MFN2 expression in tumors and lymph nodes correlated with disease progression; these proteins were decreased in breast cancer patient exosomes.

Conclusions:

  • Identified a novel mitochondrial reprogramming pathway involving SH3GL2 and MFN2 in breast cancer.
  • Frequent loss of SH3GL2 and MFN2 in breast cancer is linked to progression.
  • Circulating exosomal levels of SH3GL2 and MFN2 may serve as potential biomarkers for breast cancer detection.